KCT0005683
招募中
未知
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy
Pfizer Pharmacueticals Korea0 个研究点目标入组 99 人待定
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Pfizer Pharmacueticals Korea
- 入组人数
- 99
- 状态
- 招募中
- 最后更新
- 5年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Male participants who are \=4 and \<8 years of age at Screening (Visit 1\).
- •2\. Confirmed diagnosis of DMD by prior genetic testing demonstrating the presence of a mutation in the dystrophin gene consistent with DMD at Screening (Visit 1\). If the Investigator determines that the results are inconclusive, a repeat genetic testing will be allowed through the central laboratory at Screening (Visit 1\).
- •3\. Receipt of a stable daily dose of glucocorticoids (\=0\.5 mg/kg/day prednisone,prednisolone, or \=0\.75 mg/kg/day deflazacort) for at least 3 months prior to Screening (Visit 1\) and during the period between Screening (Visit 1\) and Day 1 (Visit 3\). In
- •order to comply with protocol procedures, there should also be a reasonable expectation that this daily dose of glucocorticoids will remain stable for the first 2 years of the study. A stable dose is defined as one in which any change is \=0\.2 mg/kg
- •4\. A NSAA total score \>16 and \<30 at Screening (Visit 1\).
- •5\. Ambulatory, defined as being able to walk 10 meters unassisted, at Screening (Visit 1\).
- •6\. Participants/legally acceptable representatives who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures including, potentially, open and/or needle muscle biopsies under general anesthesia.
- •7\. Participants/legally acceptable representatives who are capable of giving assent/signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the assent/informed consent document (ICD) and in this protocol.
- •8\. Participants/legally acceptable representatives who are willing to protect the integrity of the study data by not actively seeking sensitive clinical data (eg, CK, ALT, AST, NAb to AAV9\) through independent laboratory tests and by not sharing trial
- •experiences with other participants or publicly (eg, through social media).
排除标准
- •1\. Prior treatment with gene therapy, defined as any therapy introducing exogenous DNA or intended to permanently alter the endogenous DNA. Gene therapy (other than IP) will be prohibited for the duration of the study.
- •2\. Exposure within 6 months prior to Screening (Visit 1\) to any treatment designed to increase dystrophin expression (including, but not limited to exon\-skipping and nonsense read\-through). These treatments will also be prohibited during the period
- •between Screening (Visit 1\) and Day 1 (Visit 3\) and for the first 2 years of the study.
- •3\. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half\-lives (whichever is longer) at Screening (Visit 1\). These treatments will also be prohibited during the period between Screening (Visit 1\) and Day 1 (Visit 3\) and for the first 2 years of the study.
- •4\. Known cognitive impairment or behavioral issues that would impede the ability to follow instructions, in the judgment of the Investigator, at Screening (Visit 1\).
- •5\. Any nonhealed injury at Screening (Visit 1\) which, in the opinion of the Investigator, may impact functional testing; additionally, lower limb fractures must have been healed for at least 3 months prior to Screening (Visit 1\).
- •6\. Positive test for NAb to AAV9, based on the threshold determined by the Central Laboratory, from a sample taken at Screening (Visit 1\).
- •7\. Receipt of a live attenuated vaccination within 90 days prior to Screening (Visit 1\). Receipt of a live attenuated vaccination will also be prohibited during the period between Screening (Visit 1\) and Day 1 (Visit 3\), for 90 days prior to Year 2 IP
- •administration, and for the first 2 months after each IP administration.
- •8\. Receipt of an influenza vaccination, systemic antiviral and/or interferon therapy within 30 days prior to Screening (Visit 1\). Receipt of an influenza vaccination, systemic antiviral and/or interferon therapy will also be prohibited during the period
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
AVP-786 in the Treatment of Subjects with Agitation Associatedwith Dementia of the Alzheimer’s TypeAgitation Associated with Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code 10001497Term: AgitationSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2017-001339-38-PLOtsuka Pharmaceutical Development & Commercialization, Inc.550
进行中（未招募）
1 期
AVP-786 in the Treatment of Subjects with Agitation Associatedwith Dementia of the Alzheimer’s TypeAgitation Associated with Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code 10001497Term: AgitationSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2017-001339-38-CZOtsuka Pharmaceutical Development and Commercialization, Inc.550
进行中（未招募）
1 期
Phase 3 study to evaluate safety and effectiveness of oral Apremilast(CC-10004) in patients with Psoriatic ArthritisPsoriatic arthritis, an inflammatory arthritis that occurs in 6 to 39% of patients with psoriasis.MedDRA version: 14.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2010-018386-32-HUCelgene Corporation495
招募中
1 期
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)Atrial FibrillationMedDRA version: 20.0Level: PTClassification code: 10003658Term: Atrial fibrillation Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]CTIS2023-503224-66-00Anthos Therapeutics Inc.1,963
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus valganciclovir is in treating cytomegalovirus in hematopoietic stem cell transplant patients.EUCTR2015-004726-34-ITSHIRE HUMAN GENETIC THERAPIES, INC550